SynthesisOncotarget2017
Prognostic role of vascular endothelial growth factor in cervical cancer: a meta-analysis.
Synthesis in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic Significance of Clinicopathological Factors Influencing Overall Survival and Event-Free Survival of Patients with Cervical Cancer: A Systematic Review and Meta-Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2022Pooled it
- Enhanced Tumor-to-Background Contrast with [Pharmaceuticals (Basel, Switzerland) · 2026Article
- Preserved Menstruation After Chemoradiotherapy in Stage IIIC1 Cervical Cancer: A Unique Case.Journal of clinical medicine · 2026Article
- Review
- Personalised Medicine in Cervical Cancer: Evaluating Therapy Resistance Through Multi-Model Approaches.Cancer medicine · 2025Article
- Immunohistochemical Expression of Survivin and Vascular Endothelial Growth Factor in Cervical Squamous Cell Carcinoma.Indian journal of surgical oncology · 2025Article
- The plasma EBV DNA load with IL-6 and VEGF levels as predictive and prognostic biomarker in nasopharyngeal carcinoma.Virology journal · 2024Article
- High Expression of Vascular Endothelial Growth Factor, Ki-67, and Protein 53 are Risk Factors for Poor Response of Paclitaxel-Carboplatin Neoadjuvant Chemotherapy in Stadium IB3, IIA2, and IIB Cervical Cancer.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Pharmacotherapy for cervical cancer: current standard of care and new perspectives.Expert opinion on pharmacotherapy · 2024Review
- Expression of Vascular Endothelial Growth Factor-A (VEGF-A) in Adenocarcinoma and Squamous Cell Cervical Cancer and Its Impact on Disease Progression: Single Institution Experience.Medicina (Kaunas, Lithuania) · 2023Article
- In Vivo Preclinical Assessment of the VEGF Targeting Potential of the Newly Synthesized [Diagnostics (Basel, Switzerland) · 2023Article
- Unveiling diagnostic and therapeutic strategies for cervical cancer: biomarker discovery through proteomics approaches and exploring the role of cervical cancer stem cells.Frontiers in oncology · 2023Review
- Exploration of biomarkers for the diagnosis, treatment and prognosis of cervical cancer: a review.Discover oncology · 2022Review
- Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer.Cancers · 2021Review
- Article
- Morphological Characteristics and Clinical Significance of Different Types of Tumor Vessels in Patients with Stages I-IIA of Squamous Cervical Cancer.Journal of oncology · 2020Article
- Network Pharmacology-Based Strategy for Predicting Therapy Targets of Traditional Chinese Medicine Xihuang Pill on Liver Cancer.Evidence-based complementary and alternative medicine : eCAM · 2020Article
- Expression of BDNF, TrkB, VEGF and CD105 is associated with pelvic lymph node metastasis and prognosis in IB2-stage squamous cell carcinoma.Experimental and therapeutic medicine · 2019Article
- Association Between VEGF Expression and Diffusion Weighted Imaging in Several Tumors-A Systematic Review and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2019Article
- Th17 response in patients with cervical cancer.Oncology letters · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prognostic role of vascular endothelial growth factor (VEGF) in cervical cancer is controversial to date. The aim of this study was to evaluate the prognostic value of VEGF and VEGF-C in patients with cervical cancer. Relevant studies were identified by systematic search of the PubMed and Embase database. The primary data of eligible studies was hazard ratio (HR) with 95% confidence interval (95% CI) of survival outcomes, including overall survival (OS), disease-free survival (DFS) and progression-free survival (PFS). Pooled HR (95% CI) was calculated to evaluate the prognostic role of VEGF and VEGF-C in cervical cancer patients. The methodological qualities of the included studies were assessed using REMARK. Fourteen eligible articles including 1306 patients were included in the meta-analysis. The pooled HRs (95% CIs) of VEGF for OS and DFS/PFS were 2.29 [1.27, 4.14] and 2.77 [1.37, 5.62], respectively. The HR (95% CI) of VEGF-C for OS was 3.94 [2.22, 6.99]. This meta-analysis suggested that high expressions of VEGF and VEGF-C were significantly associated with poor survival outcome in cervical cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.